Navigation Links
Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008

FREMONT, Calif., Sept. 17 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced the presentation of posters at the 5th Annual RNAi Europe, taking place September 16-18, 2008 in Stockholm, Sweden. Three of Quark's scientists, Igor Mett, Hagar Kalinski, and Hagit Ashush, presented posters highlighting development of specific proprietary molecular tools facilitating target discovery, generation of potent RNAi therapeutics, and analysis of their activity and delivery in the framework of Quark's pre-clinical RNAi research.

A poster submitted by Hagar Kalinski is titled "Evaluation of siRNA Uptake in vivo in Target Tissues Using PCR-Based Quantification or in-situ Hybridization." It describes methods for analyzing spatial distribution of synthetic siRNA in target organs and tissues, including kidneys, lungs, retinas, and spinal cords, in an in vivo animal models. The quantification of siRNA delivery to target tissues and the ability to determine its cell-specific localization facilitates siRNA therapeutic development.

"Construction of Complex RNAi Libraries for Positive and Negative Phenotypic Selection of Target Genes," a poster submitted by Igor Mett, describes several of Quark's approaches to generating expressed RNAi libraries that are compatible with microarray-based positive and negative phenotypic cell selection. Part of the continuing development of Quark's BiFAR target discovery platform, these complex libraries can provide a high throughput tool to help identify targets for siRNA therapeutic development.

A third poster, submitted by Hagit Ashush, is titled "Tandem and RNAstar molecules for simultaneous silencing several genes," and evaluates the potential of complex dsRNA structures targeting two ("tandem") or three ("RNAstar") different genes in vitro. The multigene nature of pathogenesis for different diseases raises the necessity to target more than one gene at a time. At the same time, simultaneous delivery of different siRNAs targeting one and the same gene can increase the treatment specificity and reduce off-target effects.

Dr. Daniel Zurr, Quark's Chief Executive Officer, stated, "These poster presentations highlight our ongoing work to establish Quark's leadership in the field of RNAi by developing novel IP and expertise covering technology platforms that facilitate development of siRNA therapeutics. With the industry's most robust portfolio of siRNA therapeutics currently under evaluation in human clinical trials, Quark has proven its ability to advance siRNA products from discovery to the clinic."

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry that the Company believes provide Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability to deliver siRNA non invasively to organs including the eye, ear, kidney, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified, siRNA molecule to inhibit the expression of the gene RTP801, licensed to Pfizer. In addition, Quark's current clinical pipeline includes AKIi-5, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery, currently in Phase I/IIa clinical trials via systemic delivery and DGFi with open IND for prevention of delayed graft function in kidney transplantation. Based on publicly available information, Quark believes AKIi-5 was the first siRNA delivered systemically in a human clinical trial.

In addition, Quark has a broad pipeline of siRNA drug candidates based a novel structure developed internally. The Company expects to utilize the structure to develop additional RNAi drug candidates

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at

Quark Pharmaceuticals, Inc.

Juliana Friedmann

+972 89 30 5111 /

The Ruth Group (investors / media)

Sara Ephraim / Janine McCargo

(646) 536-7004 / 7033

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
2. Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
3. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
4. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
5. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
6. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
7. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
8. VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
9. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
10. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
11. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) holds ... organisation (CRO) market. The trend of outsourcing to ... margins but higher volume share for the region ... scale, however, margins in the CRO industry will ... Market ( ), finds that the ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential ... bound to proteins, copper is also toxic to cells. With a $1.3 million ... (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa ...
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software solutions leader SAP and ... to develop and pitch their BIG ideas to improve health and wellness in their ... votes to win the title of SAP's Teen Innovator, an all-expenses paid trip to ...
Breaking Biology Technology:
(Date:10/27/2015)... , Oct. 27, 2015 Synaptics Inc. (NASDAQ: ... announced that Google has adopted the Synaptics ® ... solutions to power its newest flagship smartphones, the Nexus ... --> --> ... to provide strategic collaboration in the joint development of ...
(Date:10/26/2015)... 2015  Delta ID Inc., a company focused on ... PC devices, announced its ActiveIRIS® technology powers the iris ... launched by NTT DOCOMO, INC in Japan ... smartphone to include iris recognition technology, after a very ... in May 2015, world,s first smartphone to have this ...
(Date:10/22/2015)...  Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter ended September 30, 2015.  --> ... $4.0 million, a decrease of 33% compared to $6.0 million in ... of 2015 was $2.2 million, or $0.10 per diluted share, which ... same period a year ago.  --> ...
Breaking Biology News(10 mins):